Table 1.
Baseline Characteristics and Staging Information of 184 Patients with Advanced HCC
| Characteristic | Parameter |
|---|---|
| Age (years) | 50 (42-58) |
| Sex | |
| Male | 166 (90.2%) |
| Female | 18 (9.8%) |
| Tumor number | 3 (1-11) |
| Maximum tumor diameter (cm) | 7.85 (4.75-11.7) |
| Extrahepatic metastases | 104 (56.5%) |
| Location | |
| Left | 23 (12.5%) |
| Right | 108 (58.7%) |
| Both | 50 (27.2%) |
| Unkown | 3 (1.6%) |
| Portal vein thrombosis | 112 (60.9%) |
| Cirrhosis | 102 (55.4%) |
| Ascites | 6 (3.3%) |
| Total bilirubin (µmol/L) | 15.49 (11.9-19.2) |
| ALT (U/L) | 38 (27.25-64.5) |
| AST (U/L) | 60.85 (40.4-88.5) |
| ALK (U/L) | 133.5 (94.0-201.0) |
| Platelet (/L) | 165 (122-229) |
| International normalized ratio | 1.09 (1.0-1.2) |
| Serum creatinine (µmol/L) | 62.2 (1-74) |
| Prothrombin time (s) | 12.9 (12.0-14.1) |
| AFP (ng/ml) | 1312 (98.2-14470) |
| History of surgery | 48 (26. 1%) |
| History of radiotherapy | 12 (6.5%) |
| History of chemotherapy | 38 (20.7%) |
| History of TACE | 65 (35.3%) |
| BCLC system | |
| B | 40 (21.7%) |
| C | 144 (78.3%) |
| CUPI system | |
| L | 97 (52.7%) |
| M | 85 (46.2%) |
| H | 2 (1.1%) |
| TNM system | |
| I | 8 (4.3%) |
| II | 7 (3.8%) |
| III | 65 (35.3%) |
| IV | 104 (56.5%) |
| GRETCH system | |
| A | 15 (8.2%) |
| B | 154 (83.7%) |
| C | 15 (8.2%) |
Median (IQR) and number (%) are displayed for quantitative and qualitative characteristics, respectively; BCLC, Barcelona Clinic Liver Cancer; CUPI, Chinese University Prognostic Index; ALT, alanine aminotransferase; AST, aspartate aminotransferase; ALK, alkaline phosphatase; AFP, alpha-fetoprotein; TACE, transarterial chemoembolization